ライフサイエンスコーパス: TSLP

1 TSLP + TGF-beta LCs had a mature phenotype with high sur

2 TSLP activates multiple immune cell subsets expressing t

3 TSLP expression was localized to the airway epithelium,

4 TSLP induced mitogen-activated protein kinase kinase (ME

5 TSLP production and dermatitis induced by alkalinization

6 TSLP was synergistically induced in epithelial cells by

7 TSLP, IFN-lambda and LDH were not increased by allergen

8 a), polarizing (CXCL13, IL-10, IL-13, IL-17, TSLP), and injury remodelling (fibronectin, IL-33, MMP-9

9 We also examined the genetic effects of 2 TSLP functional single nucleotide polymorphism (SNPs) on

10 minally with IL4/KIF3A (P = .019; OR, 1.25); TSLP's association persisted (P = 4.7 x 10(-5); OR, 1.37

11 The effects of cysLTs, PGD2, IL-33, IL-25, TSLP, and IL-2 alone or in combination on ILC2s were def

12 ression levels of IL-5, IL-13, IL-25, IL-33, TSLP and GATA3 were determined using qRT-PCR.

13 IL-4, TSLP, IL-17A, EPO activity, total cell count and specifi

14 y has been associated with variants at 5q22 (TSLP) and 2p23 (CAPN14), indicating roles for allergic s

15 nct genetic susceptibility elements at 5q22 (TSLP) and 2p23 (CAPN14).

16 pressed skin cancer development in mice in a TSLP-dependent manner.

17 +) cells) and IL-13(+) ILC2s, emergence of a TSLP receptor-positive IL-9(+) ILC2 population, and an i

18 ILC2 proliferation and activation through a TSLP-dependent mechanism in a murine model and suggest t

19 arly induced IL-13-producing ILC2s through a TSLP-dependent mechanism.

20 However, knowledge about TSLP receptor expression and functional consequences of

21 Although TSLP's role in the promotion of Th2 responses has been s

22 iations of variants in SPINK5 (P = .003) and TSLP (P = .006) with childhood asthma; a SPINK5 single n

23 uncated products, TSLP (residues 29-124) and TSLP (131-159).

24 The cytokines IL-25 and TSLP, similarly promote proinflammatory tissue responses

25 We reasoned that IL-33 and TSLP expression are also induced by RV infection in imma

26 nfection of 6-d-old mice increased IL-33 and TSLP protein abundance.

27 Administration of intranasal IL-33 and TSLP was sufficient for mucous metaplasia.

28 hanced the effect of PGD2, IL-25, IL-33, and TSLP, resulting in increased production of type 2 and ot

29 among the innate cytokines IL-25, IL-33, and TSLP.

30 IL-7 and TSLP abrogated this inhibition and induced steroid resis

31 chemokines and cytokines, such as CCL17 and TSLP in AD, and CCL20 and IL-19 in psoriasis.

32 our controls were immunostained for CD1c and TSLP receptor (TSLPR).

33 filtrating pathogenic effector Th2 cells and TSLP.

34 elial cell-intrinsic IKKalpha expression and TSLP in regulating ILC3 responses required to maintain i

35 To determine whether variations in FLG and TSLP genotype corresponded to differences in treatment u

36 Evaluation of FLG and TSLP genotypes.

37 ficant correlation between EET formation and TSLP expression (P = 0.02) as well as psoriasin expressi

38 circulating in patients with active LCH, and TSLP and TGF-beta are potential drivers of Langerhans-li

39 TRAIL regulates MID1 and TSLP, inflammation, fibrosis, smooth muscle hypertrophy,

40 en genetic variation in the SSTR1-MIPOL1 and TSLP-SLC25A46 loci and age at onset is the first report

41 Lung tissue histology, neutrophils and TSLP, TNF-alpha, IFN-beta and IFN-lambda mRNA were exami

42 Both OX40L and TSLP have been implicated in the negative regulation of

43 he relationship between these phenotypes and TSLP genotypes.

44 The SPINK5 and TSLP epistasis was replicated in a black population (P =

45 we genotyped 29 variants in FLG, SPINK5, and TSLP in asthmatic, allergic, and nonallergic nonasthmati

46 CCL11, CCL20, IL-5, IL-13, IL-25, TGFB, and TSLP.

47 We inoculated 6-d-old BALB/c (wild-type) and TSLP receptor-knockout mice with sham HeLa cell lysate o

48 tory responses of C57BL/6 wild-type (WT) and TSLP receptor-deficient (TSLPR KO) mice.

49 Limited ZsG and TSLP mRNA was observed in bone marrow-derived mast cells

50 An anti-TSLP antibody abrogated airway hyperresponsiveness, infl

51 An anti-TSLP antibody abrogates all pathologic features of asthm

52 knockout (KO), or WT mice receiving an anti-TSLP neutralizing antibody were infected with the RSV st

53 onal antibody therapies (anti-OX40L and anti-TSLP) on Treg frequency using a human model of allergic

54 AMG 157 is a human anti-TSLP monoclonal immunoglobulin G2lambda that binds human

55 Whether anti-TSLP therapeutics will have clinical value cannot be det

56 However, TH2 cytokines attenuated TSLP-mediated CCR7 induction, thus inhibiting the TSLP-i

57 Because TSLP shares signaling components with IL-7, a cytokine i

58 ignificant association was not found between TSLP and eczema or allergic sensitization.

59 bly, there was gene-gene interaction between TSLP and IL4 SNPs (P = .0074).

60 When compared to mDCs from controls, both TSLP- and Der p-pulsed blood mDCs from AA patients induc

61 In current or past smokers, both TSLP SNPs (rs2289276 and rs3860933) were associated with

62 t blockade of IL-1 signaling suppresses both TSLP and IL-23 expression and ameliorates skin inflammat

63 ence of IL-4, renders DCs responsive to both TSLP and IL-7.

64 he local support of antiviral CD8 T cells by TSLP is well suited to the mucosa, where responses must

65 ffector of type 2 immune responses driven by TSLP and suggests that dysregulation of this innate syst

66 siveness 3 weeks post-challenge as judged by TSLP receptor levels in 24-hour cultures.

67 d lung homing of HPCs may be orchestrated by TSLP and IL-33 through an IL-13-dependent axis.

68 allergen might be driven at least in part by TSLP.

69 vator of transcription (STAT) 5 signaling by TSLP.

70 Contrary to our expectations, circulating TSLP was not significantly associated with eczema, aller

71 Early presence of circulating TSLP was significantly associated with reduced incidence

72 We investigated whether circulating TSLP is associated with eczema, allergic sensitization,

73 aR, and was dependent on the innate cytokine TSLP and TGF-beta.

74 ence of this response on the innate cytokine TSLP.

75 in DC induced by the Th2-promoting cytokine TSLP, as well as the production of IL-13, IL-4, and IL-5

76 athelicidin LL-37, psoriasin) and cytokines (TSLP, IL-25, IL-32, IL-33) were elevated in EoE as compa

77 recurrent wheezing, children with detectable TSLP at one year of age were significantly less likely t

78 pared with those children without detectable TSLP, but this was only seen in children without aeroall

79 We detected TSLP in 33% of 236 children for whom plasma samples were

80 at 8 h (P < 0.05 to P < 0.0001 vs. diluent); TSLP was undetectable; IL-10, IL-17A, and IL-33 were unc

81 ice and recombinant TRAIL induced esophageal TSLP expression in vivo in the absence of allergen.

82 Finally, TSLP was required for maximal ILC2 gene expression in re

83 BAL fluid TSLP levels correlated (r = 0.74) with steroid resistanc

84 For TSLP-WDR36 region, rs3806932 (G allele protective agains

85 wing that DCs are primed in human asthma for TSLP-driven induction of both Th2 and Th9 cells.

86 IL-7Ralpha expression on DCs is critical for TSLP responsiveness and that IL-4 can upregulate IL-7Ral

87 llenge on expression levels of receptors for TSLP (thymic stromal lymphopoietin receptor [TSLPR] and

88 2 intracellular cytokines, and receptors for TSLP, IL-3, and eotaxin in blood, bone marrow, and sputu

89 These results demonstrate a role for TSLP and IL-25 in the atopic march from skin sensitizati

90 cancer and establish a fundamental role for TSLP and Th2 cells in tumor immunity against early-stage

91 TSLP receptor (TSLPR), yet a direct role for TSLP in CD8 T cell immunity in the mucosa has not been d

92 t BAC appears to be a faithful surrogate for TSLP expression, particularly in keratinocytes and medul

93 of TSLP to generate a stable dimerized form, TSLP (29-124 + 131-159), in NPs.

94 ide bonds and presented as a dimerized form, TSLP (29-124 + 131-159).

95 identified four cytokines (IL-6, IFN-gamma, TSLP and TGF-beta) that did not signal via the common ga

96 first evidence implicating roles for hepatic TSLP signaling, type 2 immunity, and eosinophilia in med

97 However, TSLP has pleiotropic effects upon immune cells, and alth

98 nal immunoglobulin G2lambda that binds human TSLP and prevents receptor interaction.

99 We incubated recombinant human TSLP with NP extracts, and determined the protein sequen

100 Our results identify TSLP as a novel player within the complex psoriasis cyto

101 We wanted to identify TSLP-responding DC populations in the human upper airway

102 re attenuated by anti-IL-33 treatment and in TSLP receptor-knockout mice.

103 SNPs in TSLP may affect asthma risk through up-regulating TSLP m

104 of asthma-related genes documenting SNPs in TSLP, GSDMB, IL33, HLA-DQB1, C11orf30, DEXI, CDHR3, and

105 everal epithelium-derived factors, including TSLP, in inducing IL-23 production by human DCs.

106 Increased TSLP and TGF-beta levels were detected in patients with

107 fluid from asthmatic patients had increased TSLP but not IL-7 levels.

108 ILC2s from asthmatic patients with increased TSLP levels were steroid resistant, which was reversed b

109 f the IL-33 receptor paradoxically increases TSLP production, which stimulates the emergence of IL-9(

110 ly, calcipotriol plus 5-FU treatment induced TSLP, HLA class II, and natural killer cell group 2D (NK

111 Moreover, the short isoform TSLP ameliorates experimental colitis in mice and preven

112 on of Th2 and Th1 cells induces keratinocyte TSLP expression.

113 tranasal rhinovirus-(RV)-1B followed by lung TSLP immunostaining.

114 nnate cytokine thymic stromal lymphopoietin (TSLP) acting on mast cells to generate PGD2 and facilita

115 nnate cytokine thymic stromal lymphopoietin (TSLP) and also induced another innate cytokine, IL-33.

116 ensitized with thymic stromal lymphopoietin (TSLP) and antigen to repeated oral doses of the same ant

117 Thymic stromal lymphopoietin (TSLP) and calpain 14 (CAPN14) genetic variations contrib

118 sly, driven by thymic stromal lymphopoietin (TSLP) and IL-23, respectively.

119 tokines IL-33, thymic stromal lymphopoietin (TSLP) and IL-25 in the activation of ILC2s, but the sour

120 Thymic stromal lymphopoietin (TSLP) and IL-33 are considered important initiators of t

121 Both thymic stromal lymphopoietin (TSLP) and IL-33 levels were increased 12 hours after inf

122 ased levels of thymic stromal lymphopoietin (TSLP) and IL-5 in the skin.

123 Thymic stromal lymphopoietin (TSLP) and IL-7 are related cytokines that mediate growth

124 th recombinant thymic stromal lymphopoietin (TSLP) and TRAIL.

125 ent as well as thymic stromal lymphopoietin (TSLP) and transforming growth factor beta (TGF-beta) pla

126 rived cytokine thymic stromal lymphopoietin (TSLP) and type 2 immunity, in particular, interleukin-4

127 25, IL-33, and thymic stromal lymphopoietin (TSLP) are associated with FA, and mAbs to these cytokine

128 teractions and thymic stromal lymphopoietin (TSLP) are important in the induction and maintenance of

129 l induction of thymic stromal lymphopoietin (TSLP) at a distant site leads to robust antitumor immuni

130 rproduction of thymic stromal lymphopoietin (TSLP) by IECs, which negatively regulated IL-22 producti

131 Thymic stromal lymphopoietin (TSLP) controls allergic TH2 inflammatory responses throu

132 (SPINK5), and thymic stromal lymphopoietin (TSLP) gene variants and childhood asthma.

133 ssociated with thymic stromal lymphopoietin (TSLP) genotype.

134 Thymic stromal lymphopoietin (TSLP) has emerged as an important cytokine in the pathog

135 Thymic stromal lymphopoietin (TSLP) is a cytokine primarily produced by epithelial cel

136 Thymic stromal lymphopoietin (TSLP) is a cytokine produced mainly by epithelial cells

137 Thymic stromal lymphopoietin (TSLP) is a cytokine with pleiotropic functions in the im

138 Thymic stromal lymphopoietin (TSLP) is a major proallergic cytokine that promotes TH2

139 Thymic stromal lymphopoietin (TSLP) is a pro-allergic cytokine implicated in AD.

140 Thymic stromal lymphopoietin (TSLP) is a type I cytokine that plays a central role in

141 Thymic stromal lymphopoietin (TSLP) is an epithelial-cell-derived cytokine that may be

142 Thymic stromal lymphopoietin (TSLP) is an epithelium-derived cytokine that induces a r

143 Thymic stromal lymphopoietin (TSLP) is known to be elevated and truncated in nasal pol

144 RATIONALE: Thymic stromal lymphopoietin (TSLP) is known to be elevated and truncated in nasal pol

145 , skin-derived thymic stromal lymphopoietin (TSLP) mediates progression from eczema to asthma.

146 ression of the thymic stromal lymphopoietin (TSLP) proinflammatory cytokine.

147 sally produced thymic stromal lymphopoietin (TSLP) regulates Th2 responses by signaling to dendritic

148 Thymic stromal lymphopoietin (TSLP) released after antigenic stimulation of allergic a

149 , resulting in thymic stromal lymphopoietin (TSLP) secretion and a cutaneous T-helper 2 allergic resp

150 with IL-7 and thymic stromal lymphopoietin (TSLP), 2 ligands of IL-7 receptor alpha.

151 we report that thymic stromal lymphopoietin (TSLP), a keratinocyte-derived cytokine involved in epith

152 tion increased thymic stromal lymphopoietin (TSLP), an upstream pro-allergic cytokine, in asthmatic b

153 25, IL-33, and thymic stromal lymphopoietin (TSLP), are elaborated by sinus epithelial cells in respo

154 sion levels of thymic stromal lymphopoietin (TSLP), cathelicidin, proteases, that is, the kallikreins

155 , IL-7, IL-12, thymic stromal lymphopoietin (TSLP), IL-25, and IL-33).

156 okines such as thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 may drive the progression from a

157 e in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar

158 mRNA for sHBEC thymic stromal lymphopoietin (TSLP), IL33, POSTN, and IL25 and downstream targets in s

159 rived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled de

160 ied that human thymic stromal lymphopoietin (TSLP), previously shown to be induced during skin inflam

161 nes, IL-33 and thymic stromal lymphopoietin (TSLP), to the observed asthma-like phenotype have not be

162 5), IL-33, and thymic stromal lymphopoietin (TSLP), which nonredundantly activated resident innate ly

163 33), IL-25 and thymic stromal lymphopoietin (TSLP).

164 25), IL-33 and thymic stromal lymphopoietin (TSLP).

165 atory cytokine thymic stromal lymphopoietin (TSLP).

166 13, IL-31, and thymic stromal lymphopoietin (TSLP); pro-inflammatory cytokines, such as IL-1beta, IL-

167 tokines (e.g., thymic stromal lymphopoietin [TSLP]) activating human basophils remains controversial.

168 33, IL-25, and thymic stromal lymphopoietin [TSLP]) and mast cell mediators (prostaglandin D2 [PGD2])

169 ays (ie, IL22, thymic stromal lymphopoietin [TSLP], CCL22, and CCL26).

170 2 innate lymphoid cells compared with mature TSLP.

171 A metabolite TSLP (29-130 + 131-159) strongly activated myeloid dendr

172 enerated a heterodimeric unstable metabolite TSLP (29-130 + 131-159).

173 Moreover, TSLP rapidly induced CCR7 expression on CD1c(+) DCs.

174 Moreover, TSLP-induced immunity also blocked early stages of pancr

175 s study the development of a reporter mouse (TSLP-ZsG) in which a ZsGreen (ZsG)-encoding construct ha

176 This novel TSLP/mDC/Th9 axis operates through a distinct, OX40L-ind

177 In contrast, the presence or absence of TSLP minor alleles did not affect asthma risk in subject

178 fications control the functional activity of TSLP in humans and overproduction of TSLP may be a key t

179 We then tested the immune activity of TSLP isoforms both in vitro and in vivo.

180 diately at the translation initiating ATG of TSLP.

181 We suggest that the capacity of TSLP to both induce Th2 differentiation and to be induce

182 Target cells of TSLP in Th2 responses include CD4 T cells and dendritic

183 s have also been shown to be target cells of TSLP.

184 We have solved the dilemma of TSLP being both homeostatic and inflammatory.

185 ied human basophils to measure the effect of TSLP on degranulation, expression of activation markers

186 this study was to investigate the effect of TSLP stimulation on human basophil function.

187 verlapping but partially distinct effects of TSLP and Der p allergen pathways, showing that DCs are p

188 Th2 cells mediated the antitumor effects of TSLP, challenging the notion that Th2 cells only promote

189 treatment blocks MC903-induced expression of TSLP and reverses impaired keratinocyte differentiation.

190 za infection induces the early expression of TSLP by lung epithelial cells with multiple consequences

191 were correlated with decreased expression of TSLP in BAL (P = 7.9 x 10(-11) and 5.4 x 10(-4) , respec

192 ough it has been reported that expression of TSLP receptor (TSLPR) on CD4 T cells is required for OVA

193 Expression of TSLP, IL33, and POSTN mRNA was increased in sHBECs in as

194 Levels of the cleaved active form of TSLP were increased in nasal polyps from patients with A

195 e protein sequence of the truncated forms of TSLP using Edman protein sequencing and matrix-assisted

196 -alpha and IL-4/IL-13 are potent inducers of TSLP expression by keratinocytes and that local activati

197 nhaled antigen through combined induction of TSLP, IL-33, and OX40 ligand and that this can lead to s

198 were treated with TSLP plus ACh, instead of TSLP or ACh alone.

199 Indeed, targeting of the long isoform of TSLP at the C-terminal portion, which is common to both

200 The long isoform of TSLP is proinflammatory and is only expressed during inf

201 of the relationship between plasma levels of TSLP to allergic sensitization and recurrent wheezing wa

202 tumors exposed to high circulating levels of TSLP were arrested at an early adenoma-like stage and we

203 Loss of TSLP receptor (TSLPR) signaling specifically in regulato

204 The main mechanism of TSLP profibrotic effects is not as yet fully understood,

205 y in the respiratory tract and modulation of TSLP levels may promote long-term CD8 T cell immunity in

206 Additionally, neutralization of TSLP significantly attenuated the RSV-induced IL-13-prod

207 vity of TSLP in humans and overproduction of TSLP may be a key trigger for the amplification of type

208 re nor the role of the truncated products of TSLP has been studied.

209 volved in the tissue-selective regulation of TSLP transcription in epidermal keratinocytes and IEC.

210 In this study we investigated the role of TSLP and IL-33 in the recruitment of progenitor cells to

211 We sought to investigate the role of TSLP in atopic, nonatopic and viral-induced exacerbation

212 We further dissected the role of TSLP in patients with psoriasis, an IL-23-associated ski

213 the understanding of the surprising role of TSLP in the control of a variety of cancers, both solid

214 at should be considered in future studies of TSLP-dependent contact sensitization and skin immune res

215 from the C terminus of the longer subunit of TSLP to generate a stable dimerized form, TSLP (29-124 +

216 ggest the potential therapeutic targeting of TSLP during severe RSV infection.

217 Therapeutic targeting of TSLP may interfere with tissue LC repopulation from circ

218 e rate-limiting enzymes in the truncation of TSLP between residues 130 and 131 and generated a hetero

219 investigate the mechanisms of truncation of TSLP in NPs and the function of the truncated products.

220 mmation in Il17ra(-/-) mice was dependent on TSLP, but not the other alarmins IL-25 and IL-33.

221 d they should lead to mechanistic studies on TSLP profibrotic signaling.

222 cells (IL-5, IL-13, and GATA3+), while only TSLP-mDCs promoted Th9 cells (IL-9 and PU.1+ /IRF4+).

223 Abs to IL-33 or recombinant IL-33, IL-25, or TSLP.

224 The inability to detect IL-33 or TSLP, or to neutralize their activity, suggested a uniqu

225 nalyses was the number of FLG LOF alleles or TSLP SNPs rather than the absolute presence or absence o

226 cted with anti-IL-25, IL-33 receptor, and/or TSLP mAbs before initial oral gavage with MCT/EW to supp

227 ction of an mAb to IL-25, IL-33 receptor, or TSLP strongly inhibited FA development.

228 sfunction, itch, and dermatitis via the PAR2-TSLP pathway.Journal of Investigative Dermatology accept

229 Whole nasal polyp TSLP mRNA expression correlated strongly with mRNA encod

230 led that mouse and human hepatocytes produce TSLP and eotaxins in response to treatment with combinat

231 tracts generated 2 major truncated products, TSLP (residues 29-124) and TSLP (131-159).

232 ocytes and that LIGHT could directly promote TSLP expression in these cells.

233 Recombinant TSLP induced PGD2 generation by cultured human mast cell

234 Injection of recombinant TSLP also induced scratching behavior in the SPF NC/Tnd

235 may affect asthma risk through up-regulating TSLP mRNA expression or protein secretion.

236 sHBEC TSLP mRNA expression was strongly associated with sDC OX

237 In situ TSLP was strongly expressed by keratinocytes of untreate

238 In human subjects TSLP is present in 2 isoforms, short and long.

239 psilonRI and anti-IgE antibodies, on surface TSLP receptor in 24-hour PBMC cultures.

240 esign of therapeutic interventions targeting TSLP in asthma.

241 ders, it is becoming increasingly clear that TSLP may impact multiple disease states within multiple

242 These findings support the concept that TSLP plays a role in the development of fibrosis, and th

243 We demonstrate that TSLP enhances human CD14(+) monocyte CCL17 production in

244 Together, our findings demonstrate that TSLP potently induces immunity directed against early st

245 We also discovered that TSLP is expressed by the breast tumor cells themselves a

246 We found that TSLP synergized with CD40 ligand to promote DC activatio

247 We further hypothesized that TSLP is induced at dsRNA- and rhinoviral infection-induc

248 temic infection models, we hypothesized that TSLP spatially and nonredundantly supports the developme

249 eukin (IL)-17A in the lungs, indicating that TSLP negatively regulates IL-17A.

250 ivated Th2 cells raises the possibility that TSLP may be involved in a positive feedback loop to enha

251 The authors also report that TSLP is able to activate fibrocytes, probably by inducin

252 Shin et al. report that TSLP may also play a role in the pathogenesis of keloids

253 We showed that TSLP isoforms are responsible for 2 opposite immune func

254 Taken together, these data suggest that TSLP uniquely participates in local immunity in the resp

255 Our results suggest that TSLP-mediated activation of human nasal mucosal CD1c(+)

256 The TSLP isoform ratio is altered during several inflammator

257 The TSLP variation is associated with less persistent AD.

258 the human upper airway mucosa and assess the TSLP-mediated effects on such DCs in allergic airway res

259 n is shaped by counterregulation between the TSLP/type 2 and IL-23/type 17 axes.

260 Activated CD8 T cells express the TSLP receptor (TSLPR), yet a direct role for TSLP in CD8

261 These data further highlight the TSLP pathway as a relevant target in human asthma.

262 transcription factors and DBS present in the TSLP promoter region are differentially used in intestin

263 r protein 1 (AP1), STAT, and Smad DBS in the TSLP promoter region.

264 cognate DNA-binding sequence(s) (DBS) in the TSLP promoter regulatory region.

265 mediated CCR7 induction, thus inhibiting the TSLP-induced DC migration potential to the draining lymp

266 tor 2 signaling is involved in mediating the TSLP/type 2 axis, whereas skin bacteria are engaged in i

267 vestigate the differential expression of the TSLP isoforms and discern their biological implications

268 more SPINK5 risk alleles, the absence of the TSLP protective minor alleles was associated with a sign

269 e had previously reported association of the TSLP/WDR36 locus with EoE.

270 We found that the TSLP receptor was constitutively and preferentially expr

271 matory or microbial stimuli and binds to the TSLP receptor (TSLPR) complex, a heterodimer composed of

272 Using the TSLP-ZsG reporter mouse, we show that TNF-alpha and IL-4

273 both solid tumors and leukemia, in which the TSLP/TSLP receptor axis was shown to be an important reg

274 Therefore, TSLP may be a potential therapeutic target for the treat

275 uced exacerbation also increased lung tissue TSLP (P < 0.05).

276 ions including the regulation of lung tissue TSLP, TNF-alpha, IFN-beta and IFN-lambda.

277 Pre-exposure to TSLP and IL-33 primed the migration of HPCs to a potent

278 cluding cytokine production and migration to TSLP and IL-33, were assessed in vitro.

279 rine basophils have been shown to respond to TSLP independently of IL-3 by increasing functional thym

280 Basophils responded to TSLP at a similar magnitude and potency as the well-desc

281 e-negative (TN) DC," is highly responsive to TSLP.

282 he TLR4 agonist LPS, their responsiveness to TSLP is poorly defined.

283 rine ex vivo splenic DCs are unresponsive to TSLP, as they fail to phosphorylate STAT5, but in vitro

284 ated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU)

285 tigated the functional activity of truncated TSLP using a PBMC-based bioassay.

286 n of human lung epithelial cells upregulated TSLP and IL-33 expression.

287 but not in non-atopic controls, upregulated TSLP receptor upon IgE receptor ligation.

288 While TSLP responses were not required during oral allergen ch

289 with IL-3 +/- anti-IgE were coincubated with TSLP, IL-33, or IL-25.

290 ated with asthma) showed no correlation with TSLP expression levels.

291 Incubation with TSLP and IL-33 stimulated significant production of IL-5

292 -6); odds ratio [OR], 1.87), moderately with TSLP (P = 1.5 x 10(-4); OR, 1.43), and nominally with CA

293 Cells were pulsed with TSLP or Dermatophagoides pteronyssinus (Der p) allergen,

294 -3(+), dendritic cells (DCs) stimulated with TSLP and TGF-beta harbor a typical CD1a(+)Langerin(+) LC

295 lood-derived mast cells were stimulated with TSLP in vitro to assess PGD2 generation.

296 In vitro stimulation with TSLP primed basophil migration to eotaxin and induced ra

297 (FLG) loss-of-function mutation, those with TSLP variation were more likely to have less-persistent

298 s further enhanced when DC were treated with TSLP plus ACh, instead of TSLP or ACh alone.

299 Treatment with TSLP reconstituted hallmark features of EoE in TRAIL(-/-

300 tween EoE-predisposing polymorphisms (within TSLP, LOC283710/KLF13, CAPN14, CCL26, and TGFB) and impl